Serum soluble interleukin-2 receptor and immunohistochemical staining of IL-2R/Tac antigen in gastric cancer

胃癌血清可溶性白细胞介素2受体及IL-2R/Tac抗原免疫组化染色

• 批准号: 11671269
• 负责人: MURAKAMI Saburo
• 金额: $ 2.18万
• 依托单位: Saitama Medical School
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1999
• 资助国家: 日本
• 起止时间: 1999 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-11671269/
• 关键词: gastric cancer; Il-2R; Tac antigen; cytokine; Colorectal cancer; Intestinal immune system

In the present study, we investigated the clinical significance of serum sIL-2R in patients with early gastric cancer. 215 patients with gastric cancer were enrolled in this study. Levels of serum soluble IL-2R were measured by an enzyme-linked immunosorbent assay. The levels of sIL-2R in cases with metastatic lymph nodes were significantly higher than those without metastatic lymph nodes. Moreover, Levels of serum sIL-2R in 74 patients with early gastric cancer were measured. Five of these 6 cases with metastatic lymph nodes demonstrated positive levels of serum soluble IL-2R, while 43 of 68 cases without metastatic lymph nodes demonstrated negative levels of serum sIL-2R. In the tissues obtained from 19 cases, immunohistochemical staining was performed with mouse anti-human interleukin-2 receptor antibody. 13 of 19 cases showed Il-2R positive cells in gastric cancer tissues. Similarly, Il-2R positive cells were recognized in the tissues of metastatic lymph nodes. These results may suggest that activated T lymphocytes infiltrating into the cancer tissues play an atitumor role and release a large amount of sIL-2R, resulting the high levels of serum sIL-2R in patients with gastric cancer. Moreover, we could get the same results in colorectal cancer as in gastric cancer. According to these data, T-lymphocytes, stimulated by humoral mediator released from cancer cells, would become to be activated T-lymphocytes, resulting in the anti-tumor effects in gastrointestinal cancer.

在本研究中，我们探讨了血清sIL-2R在早期胃癌患者中的临床意义。 215 名胃癌患者参与了这项研究。通过酶联免疫吸附测定法测量血清可溶性IL-2R水平。有转移淋巴结的患者sIL-2R水平显着高于无转移淋巴结的患者。此外，还检测了74例早期胃癌患者的血清sIL-2R水平。 6例有转移淋巴结的病例中有5例血清可溶性IL-2R呈阳性，而68例无转移淋巴结的病例中有43例血清sIL-2R呈阴性。对19例的组织进行小鼠抗人白细胞介素2受体抗体进行免疫组织化学染色。 19例胃癌组织中有13例显示Il-2R阳性细胞。类似地，在转移淋巴结的组织中识别出Il-2R阳性细胞。这些结果可能提示浸润癌组织的活化T淋巴细胞发挥抗肿瘤作用并释放大量sIL-2R，导致胃癌患者血清sIL-2R水平较高。此外，我们在结直肠癌中可以获得与胃癌相同的结果。根据这些数据，T淋巴细胞在癌细胞释放的体液介质的刺激下，会变成活化的T淋巴细胞，从而在胃肠道癌症中发挥抗肿瘤作用。

项目成果

村上三郎 その他: "早期胃癌患者におけるリンパ節転移予知因子としての血中可溶性IL-2R値."外科治療. 84・2. 241-242 (2001)

Saburo Murakami 等：“可溶性 IL-2R 水平作为早期胃癌患者淋巴结转移的预测因子。”84・2（2001）。

Sakata H, Murakami S, Hirayama R: "Serum soluble IL-2R and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer"International Journal of Clinical Oncology. 7・5. 312-317 (2002)

Sakata H、Murakami S、Hirayama R：“结直肠癌中的血清可溶性 IL-2R 和 IL-2R/Tac 抗原的免疫组织化学染色”国际临床肿瘤学杂志 7・5（2002 年）。

Murakami S, Sakata H, Tsuji Y, Hirayama R, et al.: "Serum soluble IL-2R as a predictor of lymph node metastasis in early gastric cancer"Digestive Surgery. 19・1. 9-14 (2002)

Murakami S、Sakata H、Tsuji Y、Hirayama R 等：“血清可溶性 IL-2R 作为早期胃癌淋巴结转移的预测因子”19・1（2002 年）。

Saburo Murakami, et al.: "Serum soluble interleukin-2 receptor as a predictor of lymph node metastasis in early gastric cancer"Digestive Surgery. Vol19(in press). (2002)

Saburo Murakami 等人：“血清可溶性白细胞介素 2 受体作为早期胃癌淋巴结转移的预测因子”消化外科。

Sakata Hideto, Saburo Murakami, Renzo Hirayama: "Serum soluble IL-2R and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer"International Journal of Clinical Oncology. 17(5). 312-317 (2002)

Sakata Hideto、Saburo Murakami、Renzo Hirayyama：“结直肠癌中血清可溶性 IL-2R 和 IL-2R/Tac 抗原的免疫组织化学染色”国际临床肿瘤学杂志。